Vaccination during pregnancy reduces the risk of COVID-19 infection in newborns

Researchers in Norway followed 9,739 children whose mothers received a second or third dose of the vaccine COVID-19 vaccine of Pfizer-BioNTech or Moderna during pregnancy and 11,904 children whose mothers were not vaccinated before or during pregnancy. In general, infection with COVID-19 is very rare in infants.

The risk of having a positive COVID-19 PCR test in the first 4 months of life is up to 71% lower during outbreaks due to the Delta variant and 33% lower when the Omicron variant predominates for infants whose mothers were vaccinated during pregnancy compared with children born to unvaccinated mothers. The results of the study were published in the journal JAMA Internal Medicine on June 1.

Dr. Ellen Oen Carlsen of the Norwegian Institute of Public Health notes that infants receive a different type of antibody from breast milk and may be due to antibodies acquired from breastfeeding or from mothers. vaccinated are less likely to get COVID-19 and pass it on to their children.

The infants of women who received booster shots during pregnancy had an even lower risk of contracting COVID-19 than women who received only two primary shots. “This means that women who have been vaccinated before becoming pregnant with two doses of the vaccine should consider getting a booster shot later in pregnancy,” Ms Carlsen said.

Vaccination during pregnancy, especially booster shots, can significantly reduce the risk of COVID-19 in newborns. (Photo: PBS.org)

In addition, according to a large study by the US Department of Veterans Affairs, the risk of developing symptoms Prolonged COVID-19 post-infection with the SARS-CoV-2 virus was lower in those who had received the COVID-19 vaccine than in those who had not been vaccinated, but this effect was not significant.

Researchers compared outcomes between nearly 34,000 people who became infected with the breakthrough SARS-CoV-2 after being vaccinated with a Johnson & Johnson, Pfizer-BioNTech or Moderna vaccine with more than 113,000 unvaccinated people who were infected. The study, conducted when the Delta variant was dominant and published in the journal Nature Medicine, found that vaccination only reduced the likelihood of contracting COVID-19 by 15 percent long after infection. There was no difference in the type or severity of persistent COVID-19 symptoms between vaccinated and unvaccinated patients.

A new approach to looking at virus evolution could help predict whether and when a new variant is likely to compete with dominant viral strains, the researchers say.

Venky Soundararajan of a Massachusetts-based data analytics firm said in a report published June 2 on medRxiv prior to the peer review, to estimate the potential impact of a variant, “calculation,” special” of the mutated gene sequence relative to previously circulating variants must be considered in the context of each geographical area. The genetic changes that give them differences in one geographic region may not be the same in another, depending on what variations are circulating there, his team says.

Using a database of nearly 8 million SARS-CoV-2 samples from around the world, the researchers tracked and compared the evolutionary genetic sequences of the variants that populations in different regions of the world have. different people have been exposed, also known as community exposure. They found that the specificity of a clan in a given country during a particular time period was significantly associated with the change in morbidity in that country eight weeks later.

* Invite readers to watch programs broadcast by Vietnam Television on TV Online and VTVGo!